AKT1 and prostate carcinoma: Perifosine, a novel AKT inhibitor [128], was evaluated in a phase I trial combining daily oral doses (50–200 mg) with fractionated radiotherapy in various advanced solid tumors, including NSCLC, bladder cancer, prostate cancer, and esophageal cancer.